Clinical Trials Directory

Trials / Unknown

UnknownNCT03581058

Neural Correlates of Driving and Cannabis

Investigating the Neural Correlates of Driving After Medical Cannabis Exposure

Status
Unknown
Phase
Phase 1
Study type
Interventional
Enrollment
12 (estimated)
Sponsor
Unity Health Toronto · Academic / Other
Sex
All
Age
25 Years – 59 Years
Healthy volunteers
Not accepted

Summary

Driving is a set of complex tasks and requires use of multiple cognitive domains, including attention, planning, and memory. In laboratory studies, the main psychoactive component in cannabis, delta-9-tetrahydrocannabinol (THC), was shown to impair short-term memory, attention, reaction time, tracking, and coordination, resulting, for instance, in significantly more deviations from the lane and increased break latency. Surveys and epidemiological studies suggest that cannabis consumption is associated with increased risks of collision. The current study aims to evaluate individual driving behavior and performance on various neurocognitive tests and their correlated neural networks while under the influence of cannabis and while sober. The investigators will use the STISIM driving simulator, which is fully MRI compatible, to study brain activation, while participants are performing various driving maneuvers. The goals of the study are: 1. identify driving performance and patterns in brain activation associated with cannabis exposure and compare them to brain patterns of the same participants while sober; 2. compare participant's performance on cognitive tasks while under the influence of cannabis and sober; 3. look for correlations between concentration of cannabinoids in the participants' blood and their driving performance and performance on cognitive tasks; 4. correlate demographic variables and personal history (e.g. tolerance to drug) with performance and brain activation while driving under the influence of cannabis.

Conditions

Interventions

TypeNameDescription
DRUGCannabisParticipants will be assigned to consume one of the cannabis strains and will complete testing immediately after consumption.

Timeline

Start date
2018-08-08
Primary completion
2020-12-31
Completion
2020-12-31
First posted
2018-07-10
Last updated
2020-03-23

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT03581058. Inclusion in this directory is not an endorsement.